Pharmaceutical firm Lupin posted a 43% growth in its consolidated net profit to R401.1 crore, against R280 crore during the same period of previous fiscal. The company?s net sales rose 10% to R2,420 crore, against R2,219 crore for the same period of the previous fiscal.
The company reported Ebitda of R580 crore, compared with R457 crore reported in the year-ago period. Ebitda margins for the June quarter rose to 24.3% for the June quarter, compared with 20.6% reported in the year-ago period.
The firm has also signed a licensing pact with US-based pharmaceutical firm Romark Laboratories to market the latter?s diarrhoea treatment drug ?Alinia? in the American market. Under the strategic licensing agreement, Lupin will get the exclusive rights to promote, distribute and market Alinia for oral suspension in the US.